Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies
Sponsor: Verastem, Inc.
Terminated
Sponsor's decision to deprioritize the program.
A PHASE1 clinical study on Metastatic Cancer and Non Hematologic Cancers, this trial is terminated or withdrawn. The trial is conducted by Verastem, Inc. and has accumulated 9 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Sep 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Verastem, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .